129 related articles for article (PubMed ID: 32013805)
1. Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy.
Bowler S; Siriwardhana C; Mitchell BI; D'Antoni ML; Ogata-Arakaki D; Souza S; Yee R; Gangcuangco LMA; Chow DC; Ndhlovu LC; Shikuma C
HIV Res Clin Pract; 2019; 20(4-5):123-129. PubMed ID: 32013805
[No Abstract] [Full Text] [Related]
2. Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression.
D'Antoni ML; Mitchell BI; McCurdy S; Byron MM; Ogata-Arakaki D; Chow D; Mehta NN; Boisvert WA; Lefebvre E; Shikuma CM; Ndhlovu LC; Baumer Y
J Leukoc Biol; 2018 Dec; 104(6):1241-1252. PubMed ID: 30088682
[TBL] [Abstract][Full Text] [Related]
3. Improved Cognitive Performance and Reduced Monocyte Activation in Virally Suppressed Chronic HIV After Dual CCR2 and CCR5 Antagonism.
DʼAntoni ML; Paul RH; Mitchell BI; Kohorn L; Fischer L; Lefebvre E; Seyedkazemi S; Nakamoto BK; Walker M; Kallianpur KJ; Ogata-Arakaki D; Ndhlovu LC; Shikuma C
J Acquir Immune Defic Syndr; 2018 Sep; 79(1):108-116. PubMed ID: 29781885
[TBL] [Abstract][Full Text] [Related]
4. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis.
Lefebvre E; Moyle G; Reshef R; Richman LP; Thompson M; Hong F; Chou HL; Hashiguchi T; Plato C; Poulin D; Richards T; Yoneyama H; Jenkins H; Wolfgang G; Friedman SL
PLoS One; 2016; 11(6):e0158156. PubMed ID: 27347680
[TBL] [Abstract][Full Text] [Related]
5. Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.
Visseaux B; Charpentier C; Collin G; Bertine M; Peytavin G; Damond F; Matheron S; Lefebvre E; Brun-Vézinet F; Descamps D;
PLoS One; 2015; 10(8):e0134904. PubMed ID: 26247470
[TBL] [Abstract][Full Text] [Related]
6. Improvement in Hepatic Fibrosis Biomarkers Associated With Chemokine Receptor Inactivation Through Mutation or Therapeutic Blockade.
Sherman KE; Abdel-Hameed E; Rouster SD; Shata MTM; Blackard JT; Safaie P; Kroner B; Preiss L; Horn PS; Kottilil S
Clin Infect Dis; 2019 May; 68(11):1911-1918. PubMed ID: 30239650
[TBL] [Abstract][Full Text] [Related]
7. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects.
Lalezari J; Gathe J; Brinson C; Thompson M; Cohen C; Dejesus E; Galindez J; Ernst JA; Martin DE; Palleja SM
J Acquir Immune Defic Syndr; 2011 Jun; 57(2):118-25. PubMed ID: 21317794
[TBL] [Abstract][Full Text] [Related]
8. Elevation of Non-Classical (CD14+/lowCD16++) Monocytes Is Associated with Increased Albuminuria and Urine TGF-β1 in HIV-Infected Individuals on Stable Antiretroviral Therapy.
Mitchell BI; Byron MM; Ng RC; Chow DC; Ndhlovu LC; Shikuma CM
PLoS One; 2016; 11(4):e0153758. PubMed ID: 27097224
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the beneficial effects of RS504393, maraviroc and cenicriviroc on neuropathic pain-related symptoms in rodents: behavioral and biochemical analyses.
Kwiatkowski K; Ciapała K; Rojewska E; Makuch W; Mika J
Int Immunopharmacol; 2020 Jul; 84():106540. PubMed ID: 32402949
[TBL] [Abstract][Full Text] [Related]
10. The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline.
Kramer VG; Hassounah S; Colby-Germinario SP; Oliveira M; Lefebvre E; Mesplède T; Wainberg MA
J Antimicrob Chemother; 2015 Mar; 70(3):750-6. PubMed ID: 25433008
[TBL] [Abstract][Full Text] [Related]
11. Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.
Files DC; Tacke F; O'Sullivan A; Dorr P; Ferguson WG; Powderly WG
PLoS Pathog; 2022 Jun; 18(6):e1010547. PubMed ID: 35749425
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice.
Ambade A; Lowe P; Kodys K; Catalano D; Gyongyosi B; Cho Y; Iracheta-Vellve A; Adejumo A; Saha B; Calenda C; Mehta J; Lefebvre E; Vig P; Szabo G
Hepatology; 2019 Mar; 69(3):1105-1121. PubMed ID: 30179264
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
Pedrosa M; Seyedkazemi S; Francque S; Sanyal A; Rinella M; Charlton M; Loomba R; Ratziu V; Kochuparampil J; Fischer L; Vaidyanathan S; Anstee QM
Contemp Clin Trials; 2020 Jan; 88():105889. PubMed ID: 31731005
[TBL] [Abstract][Full Text] [Related]
14. The Critical Role of Chemokine (C-C Motif) Receptor 2-Positive Monocytes in Autoimmune Cholangitis.
Reuveni D; Gore Y; Leung PSC; Lichter Y; Moshkovits I; Kaminitz A; Brazowski E; Lefebvre E; Vig P; Varol C; Halpern Z; Shibolet O; Gershwin ME; Zigmond E
Front Immunol; 2018; 9():1852. PubMed ID: 30158929
[TBL] [Abstract][Full Text] [Related]
15. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy.
O'Brien TR; McDermott DH; Ioannidis JP; Carrington M; Murphy PM; Havlir DV; Richman DD
AIDS; 2000 May; 14(7):821-6. PubMed ID: 10839590
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment.
Lefebvre E; Gottwald M; Lasseter K; Chang W; Willett M; Smith PF; Somasunderam A; Utay NS
Clin Transl Sci; 2016 Jun; 9(3):139-48. PubMed ID: 27169903
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
[TBL] [Abstract][Full Text] [Related]
19. The dual CCR2/CCR5 chemokine receptor antagonist Cenicriviroc reduces macrophage infiltration and disease severity in Duchenne muscular dystrophy (Dmdmdx-4Cv) mice.
Liang F; Giordano C; Shang D; Li Q; Petrof BJ
PLoS One; 2018; 13(3):e0194421. PubMed ID: 29561896
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of CNS Viral Seeding by HIV
Veenstra M; León-Rivera R; Li M; Gama L; Clements JE; Berman JW
mBio; 2017 Oct; 8(5):. PubMed ID: 29066542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
